10-Q: Kairos Pharma Reports Q2 2026 Results Amidst Going Concern Doubts

Kairos Pharma, Ltd. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing research and development activities alongside significant financial challenges and substantial doubt regarding its ability to continue as a going concern.

Summary

• Kairos Pharma, Ltd. reported its financial results for the six months ended June 30, 2026, showing no revenue and a net loss of $3.042 million.
• The company has an accumulated deficit of $17.304 million and cash and short-term investments of $2.626 million as of June 30, 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern, as noted by management and the independent auditor.
• Research and development expenses increased to $1.303 million for the six months ended June 30, 2026, compared to $989,000 in the prior year period, primarily due to Phase 2 trials.
• General and administrative expenses were $1.804 million for the six months ended June 30, 2026.
• The company continues to rely on equity and debt financings, collaborations, and licensing arrangements to fund its operations.
• Subsequent to June 30, 2026, the company raised $911,000 through its At the Market (ATM) offering.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the continued net losses, substantial doubt about the company's ability to continue as a going concern, and the lack of revenue generation. While there are ongoing R&D efforts, the financial precariousness is a significant concern.

Positives

• Research and development expenses increased, indicating continued investment in product candidates, with Phase 2 trials for prostate cancer being a key driver.
• The company has access to an At the Market (ATM) offering and an Equity Line of Credit (ELOC) to potentially raise future capital.
• Subsequent to the reporting period, the company raised $911,000 through its ATM offering, providing some immediate liquidity.
• The company has entered into agreements for pharmaceutical development services and potential asset acquisitions, signaling ongoing strategic development.

Negatives

• The company generated no revenue in the six months ended June 30, 2026, and has not generated any sales to date.
• A net loss of $3.042 million was incurred for the six months ended June 30, 2026, contributing to an accumulated deficit of $17.304 million.
• Substantial doubt exists about the company's ability to continue as a going concern, a concern highlighted by both management and the independent auditor.
• Cash and cash equivalents decreased to $2.626 million as of June 30, 2026, from $4.491 million at the end of 2025.
• The company expects its existing cash balance may not be adequate to fund planned operating expenses and capital expenditures for at least the next 12 months.
• Disclosure controls and procedures were found to be not effective at a reasonable assurance level.
• A material weakness in internal controls over financial reporting persists due to insufficient review procedures and segregation of duties.

Risks

• The company's ability to continue as a going concern is dependent on raising additional funds and implementing its strategies.
• Failure to raise sufficient capital could lead to delays or elimination of product development or commercialization efforts.
• The company may not receive all or some of the available proceeds from its ELOC and ATM offerings, exhausting capital resources sooner than expected.
• Additional financing may contain undue restrictions on operations or cause substantial dilution to shareholders.
• The success of product candidates is highly uncertain due to numerous risks associated with product development and commercialization, including regulatory approvals and market acceptance.
• Failure to satisfy NYSE American continued listing requirements could lead to delisting, severely impacting liquidity and market price.

Future Outlook

The company expects to continue incurring significant and increasing expenses and operating losses for the foreseeable future as it advances its product candidates through development, seeks regulatory approval, and operates as a public company. It anticipates needing substantial additional funding and expects its current cash balance may not be adequate to fund planned operations for at least the next 12 months.

Management Comments

• The company's ability to continue as a going concern is dependent upon the company's ability to raise additional funds and implement its strategies.
• We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel, and operate as a public company.
• We will not generate revenue from product sales unless and until we successfully complete our clinical trials and obtain regulatory approval for our product candidates.
• We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all.
• Our failure to raise capital or enter into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition.

Industry Context

StockSavvy.ai notes that Kairos Pharma operates in the highly competitive and capital-intensive biotechnology sector, focusing on oncology treatments. The company's reliance on R&D and the long, uncertain path to regulatory approval and commercialization are typical challenges for early-stage biopharma companies. The current financial situation, with significant losses and doubts about going concern, is a critical factor that investors must weigh against the potential of its therapeutic pipeline.

Comparison to Industry Standards

• Many early-stage biotechnology companies experience significant operating losses and require substantial external financing to fund research and development, which is consistent with Kairos Pharma's situation.
• The typical development timeline for a new drug, from discovery to FDA approval, can span over a decade and cost hundreds of millions of dollars, a benchmark against which Kairos Pharma's progress and funding needs should be assessed.
• Companies in the oncology space often face intense competition from established pharmaceutical giants and numerous emerging biotechs, requiring strong differentiation and robust clinical data to succeed.
• The need for continuous capital raises, whether through equity offerings or strategic partnerships, is a common characteristic of the industry, as demonstrated by Kairos Pharma's use of ATM and ELOC facilities.

Corporate Governance

Legal Proceedings

• To the Company's knowledge, it is not currently the subject of any material legal proceeding.
• The company may be involved in future legal proceedings, claims, investigations, and government inquiries arising in the ordinary course of business, including those related to intellectual property, data privacy, securities, and employment.

Related Party Transactions

• The company has agreements with Cedars-Sinai Medical Center, where Dr. Ramachandran Murali, the Vice President of Research and Development, is also a doctor and scientist and an inventor of licensed technologies.
• The company entered into a consulting agreement with Cross Current Capital LLC, and the Advisor, Alan Masley, was to receive $500 of restricted shares of the company's common stock.

Stakeholder Impact

• Shareholders may experience substantial dilution if the company raises additional capital through equity financing.
• The company's ability to continue as a going concern poses a significant risk to shareholders.
• Employees may face uncertainty due to the company's financial precariousness and potential need for further funding.
• Suppliers and creditors may face risks if the company is unable to meet its financial obligations due to a lack of funding.

Next Steps

• Continue advancing product candidates through preclinical and clinical development.
• Seek regulatory approval for current and future product candidates.
• Maintain and expand intellectual property portfolio.
• Hire additional research and development and business personnel.
• Continue to operate as a public company.
• Explore collaborations, strategic alliances, licensing arrangements, and other capital sources.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' rating. While the company is actively pursuing R&D in promising oncology areas and has access to capital-raising mechanisms, the significant net losses, accumulated deficit, and substantial doubt about its going concern status present considerable risks. The lack of revenue and the ongoing need for substantial funding necessitate caution. Investors should monitor future financing activities and clinical trial progress closely.

Keywords

biotechnology, oncology, immunotherapy, cell therapy, clinical trials, drug development, biopharmaceutical, FDA approval